公开(公告)号：US20190192643A1

公开(公告)日：2019-06-27

申请号：US16229841

申请日：2018-12-21

Applicant: BIONTECH AG ,  TRON - Translationale Onkologie an der Universitätsmedizin Mainz Gemeinnützige Gmbh

Inventor： Ugur Sahin ,  Claudia Paret ,  Kirsten Vormbrock ,  Christian Bender ,  Petra Simon ,  Christoph Hartmann ,  Stefanie Hubich ,  Thomas Bukur ,  Thorsten Litzenberger

IPC: A61K39/00 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61K2039/507 ,  A61K2039/53 ,  A61K2039/70 ,  C07K14/4748 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57415 ,  G01N33/57484 ,  G01N2333/47

Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.

公开(公告)号：US10106800B2

公开(公告)日：2018-10-23

申请号：US15217555

申请日：2016-07-22

Applicant: BioNTech AG

Inventor： Ugur Sahin ,  Silke Holtkamp ,  Ozlem Tureci ,  Sebastian Kreiter

IPC: C12N15/00 ,  C12P21/06 ,  C12N15/68 ,  C12N15/67 ,  C12N15/85

Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.

公开(公告)号：US10093736B2

公开(公告)日：2018-10-09

申请号：US14442445

申请日：2013-11-12

Applicant: Biontech AG ,  Ganymed Pharmaceuticals AG ,  TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Christiane Stadler ,  Julia Holland ,  Hayat Bahr-Mahmud ,  Tim Beissert ,  Laura Plum ,  Fabrice Le Gall ,  Arne Jendretzki ,  Markus Fiedler

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

公开(公告)号：US20180037632A1

公开(公告)日：2018-02-08

申请号：US15552215

申请日：2016-03-15

Applicant: BIONTECH AG

Inventor： Ugur Sahin ,  Joycelyn Wüstehube-Lausch ,  Markus Fiedler ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt

IPC: C07K14/81

CPC classification number: C07K14/811 ,  C12Y304/21026

Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.

公开(公告)号：US20170314078A1

公开(公告)日：2017-11-02

申请号：US15591896

申请日：2017-05-10

Applicant: BioNTech AG ,  Johannes Gutenberg-Universität Mainz

Inventor： Ugur Sahin ,  Özlem Türeci ,  Michael Koslowski

IPC: C12Q1/68 ,  C07K14/47 ,  C07K16/30

CPC classification number: C12Q1/6886 ,  C07K14/4748 ,  C07K16/30 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.

公开(公告)号：US20170218342A1

公开(公告)日：2017-08-03

申请号：US15485601

申请日：2017-04-12

Applicant: BioNTech AG ,  TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg

Inventor： Ugur Sahin ,  Marco Poleganov ,  Tim Beissert

IPC: C12N5/074

CPC classification number: C12N5/0696 ,  C12N2510/00

Abstract: The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.

公开(公告)号：US09617321B2

公开(公告)日：2017-04-11

申请号：US14457897

申请日：2014-08-12

Applicant: BioNTech AG

Inventor： Thorsten Klamp ,  Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Thomas Hiller ,  Jens Schumacher

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/005 ,  C12N7/00

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/523 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/6075 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N7/00 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2730/10143 ,  C12N2730/10171

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

公开(公告)号：US20170052187A1

公开(公告)日：2017-02-23

申请号：US14887979

申请日：2016-03-07

Applicant: BioNTech AG

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Gerd Helftenbein ,  Dirk Usener ,  Volker Schluter

IPC: G01N33/574 ,  G06F19/22 ,  C12Q1/68

CPC classification number: G01N33/57492 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G06F19/22

Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.

Abstract translation: 本发明涉及鉴定肿瘤相关基因产物并编码其核酸。 还公开了与肿瘤相关表达的肿瘤相关遗传产物异常表达的疾病的治疗和诊断，以及用于所述蛋白质，多肽和肽的编码核酸的蛋白质，多肽和肽。

公开(公告)号：US20160347815A1

公开(公告)日：2016-12-01

申请号：US15113981

申请日：2014-01-29

Applicant: BIONTECH AG ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERS ,  UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG- UNIVERSITÄT MAINZ ,  JPT PEPTIDE TECHNOLOGIES GMBH

Inventor： Ugur Sahin ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Laura Marie Plum ,  Markus Fiedler ,  Ulf Reimer ,  Karsten Schnatbaum

IPC: C07K14/705 ,  G01N33/53 ,  A61K39/00 ,  G01N33/574

CPC classification number: C07K14/705 ,  A61K39/0005 ,  G01N33/5308 ,  G01N33/57492 ,  G01N2333/705 ,  G01N2500/02 ,  G01N2500/04

Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

Abstract translation: 本发明提供模拟整合的跨膜蛋白克劳丁18.2（CLDN18.2）的抗原决定簇的分子。 这些分子与CLDN18.2竞争结合CLDN18.2结合结构域，例如。 抗体的CLDN18.2结合结构域，并且能够检测针对CLDN18.2的抗体。 本发明的模拟表位可用于产生或抑制动物和优选人类的免疫应答。 此外，它们可以用于检测在生物样品中包含CLDN18.2结合结构域的试剂以及用于包含CLDN18.2结合结构域的纯化剂的目的。

公开(公告)号：US20150314018A1

公开(公告)日：2015-11-05

申请号：US14706228

申请日：2015-05-07

Applicant: BIONTECH AG ,  TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBE ,  UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ

Inventor： Ugur Sahin ,  Tim Beissert ,  Marco Poleganov ,  Stephanie Herz ,  Lars Koste

IPC: A61K48/00 ,  C12N13/00 ,  A61K38/16 ,  A61K31/52 ,  A61K31/429

CPC classification number: A61K48/00 ,  A61K31/429 ,  A61K31/52 ,  A61K38/162 ,  C12N5/0696 ,  C12N13/00 ,  C12N2501/24 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2501/608 ,  C12N2501/65 ,  C12N2501/727 ,  C12N2506/1307 ,  C12N2510/00

Abstract: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.

Abstract translation: 本发明涉及在细胞中表达RNA，特别涉及提高RNA表达细胞的活力。 具体地，本发明提供了在细胞中表达RNA的方法，其包括以下步骤：通过细胞外IFN与IFN受体的接合并抑制细胞中的细胞内IFN信号传导。 因此，通过细胞外IFN阻止IFN受体的接合并抑制细胞中的细胞内IFN信号传导允许RNA重复转移到细胞中。